Document is current
Any future updates will be listed below
-
Authors
Martín-López, María
Rosell-Valle, Cristina
Arribas-Arribas, Blanca
Fernández-Muñoz, Beatriz
Jiménez, Rosario
Nogueras, Sonia
García-Delgado, Ana Belén
Campos, Fernando
Santos-González, Mónica https://orcid.org/0000-0002-3672-5674
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (RTC-2017-6658-1)
Instituto de Salud Carlos III (DTS17/00137)
- License Information
-
More Information
Article History
Received: 12 December 2022
Accepted: 24 March 2023
First Online: 7 April 2023
Declarations
:
: The Centro de Transfusiones, Tejidos y Células of Seville (CTTS, Sevilla, Spain), provided plasma. The Andalusian Biomedical Research Coordinator Ethical Committee through the Andalusian Public Health System Biobank approved their procurement and all donors signed an informed written consent, according to Spanish law (RD 1088/2005). The project “Development of new cryoproterctors for cell therapy” was approved by Research Ethics Committee of Hospitals Virgen Macarena- Virgen del Rocío for the procurement of plasma, BM-MSC, FB and NSC (RTC-2017-6658-1, 6th April 2019). Samples were obtained after written informed consent according to Spanish Law (RD 1301/2006).
: Not applicable.
: MM-L, CR-V and MS-G present competing interests. The commercial exploitation rights of the cryoprotective solutions based on human platelet lysate for cryopreservation of cells and tissue referred to in the present publication were licensed in exclusive, worldwide, for research use and with the right to sublicense to the company MD Bioproducts GmbH.
